BioAtla (BCAB) Retained Earnings (2020 - 2026)
BioAtla (BCAB) posted quarterly Retained Earnings of -$552.0 million for Q1 2026, down 10.1% year-over-year from -$614.0 million in Q1 2025, and down 208.35% quarter-over-quarter from $509.5 million in Q4 2025.
BioAtla (BCAB) Retained Earnings (2020 - 2026) Analysis & Trends
BioAtla's Retained Earnings history runs 7 years deep, the most recent figure standing at -$552.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 10.1% year-over-year to -$552.0 million; the TTM figure through Mar 2026 stood at -$552.0 million (down 10.1% YoY), while the FY2025 annual figure was $509.5 million, up 1.83% from the prior year.
- Retained Earnings for Q1 2026 stood at -$552.0 million, down from $509.5 million in the prior quarter.
- The five-year high for Retained Earnings was $509.5 million in Q4 2025, with the low at -$552.0 million in Q1 2026.
- The 5-year median for Retained Earnings is $480.5 million (2023), against an average of $135.7 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings tumbled 173.73% in 2022, then jumped 300.65% in 2023.
- BioAtla's Retained Earnings stood at -$292.8 million in 2022, then soared by 266.3% to $486.9 million in 2023, then advanced by 2.75% to $500.3 million in 2024, then climbed by 1.83% to $509.5 million in 2025, then tumbled by 208.35% to -$552.0 million in 2026.
- Business Quant data shows BCAB's Retained Earnings at -$552.0 million in Q1 2026, $509.5 million in Q4 2025, and $504.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | -551.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -551.54 Mn |
| Mar 31, 2026 | -551.99 Mn |
| Dec 31, 2025 | 509.46 Mn |
| Sep 30, 2025 | 504.62 Mn |
| Jun 30, 2025 | 503.33 Mn |
| Mar 31, 2025 | -501.37 Mn |
| Dec 31, 2024 | 500.30 Mn |
| Sep 30, 2024 | 494.12 Mn |
| Jun 30, 2024 | 491.93 Mn |
| Mar 31, 2024 | -439.50 Mn |
| Dec 31, 2023 | 486.93 Mn |
| Sep 30, 2023 | 484.04 Mn |
| Jun 30, 2023 | 480.52 Mn |
| Mar 31, 2023 | -320.26 Mn |
| Dec 31, 2022 | -292.80 Mn |
| Sep 30, 2022 | 407.89 Mn |
| Jun 30, 2022 | -239.48 Mn |
| Mar 31, 2022 | -210.60 Mn |
| Dec 31, 2021 | 397.14 Mn |
| Sep 30, 2021 | 393.58 Mn |